MENU
BBP
ETF ticker: NYSE ARCA
PRICE
CHANGE
NET ASSETS

BBP stock forecast, quote, news & analysis

The investment seeks investment results that correspond, before fees and expenses, to the price and yield performance of the LifeSci Biotechnology Products Index... Show more

Category: #Health
BBP
Daily Signal:
Gain/Loss:
A.I.Advisor
published price charts
Interact to see
Advertisement
A.I.Advisor
a Summary for BBP with price predictions
Sep 04, 2026

BBP in downward trend: price may decline as a result of having broken its higher Bollinger Band on August 19, 2026

BBP broke above its upper Bollinger Band on August 19, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options. The A.I.dvisor looked at 50 similar instances where the stock broke above the upper band. In of the 50 cases the stock fell afterwards. This puts the odds of success at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The 10-day RSI Indicator for BBP moved out of overbought territory on August 28, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 31 similar instances where the indicator moved out of overbought territory. In of the 31 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.

The Moving Average Convergence Divergence Histogram (MACD) for BBP turned negative on September 04, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 53 similar instances when the indicator turned negative. In of the 53 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where BBP declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on September 03, 2026. You may want to consider a long position or call options on BBP as a result. In of 92 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where BBP advanced for three days, in of 316 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 265 cases where BBP Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Amgen (NASDAQ:AMGN), Gilead Sciences (NASDAQ:GILD), Regeneron Pharmaceuticals (NASDAQ:REGN), Moderna (NASDAQ:MRNA), Biogen (NASDAQ:BIIB), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), BioCryst Pharmaceuticals (NASDAQ:BCRX), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX).

Industry description

The investment seeks investment results that correspond, before fees and expenses, to the price and yield performance of the LifeSci Biotechnology Products Index. Under normal market conditions, the fund will invest not less than 80% of its assets in component securities of the index. The index seeks to track the performance of the common stock of U.S. exchange-listed biotechnology companies with at least one drug therapy approved by the U.S. Food and Drug Administration ("FDA") for marketing.

Market Cap

The average market capitalization across the Virtus LifeSci Biotech Products ETF ETF is 21.98B. The market cap for tickers in the group ranges from 391.22M to 236.38B. AMGN holds the highest valuation in this group at 236.38B. The lowest valued company is YMAB at 391.22M.

High and low price notable news

The average weekly price growth across all stocks in the Virtus LifeSci Biotech Products ETF ETF was 2%. For the same ETF, the average monthly price growth was 12%, and the average quarterly price growth was 30%. TARS experienced the highest price growth at 27%, while RARE experienced the biggest fall at -40%.

Volume

The average weekly volume growth across all stocks in the Virtus LifeSci Biotech Products ETF ETF was -4%. For the same stocks of the ETF, the average monthly volume growth was -39% and the average quarterly volume growth was -40%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 64
P/E Growth Rating: 66
Price Growth Rating: 41
SMR Rating: 71
Profit Risk Rating: 60
Seasonality Score: -26 (-100 ... +100)
View a ticker or compare two or three
BBP
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

Category Health

Profile
Details
Category
Health
Address
501 Madison Avenue, Suite 501New YorkNew York
Phone
(212) 593-4383
Web
N/A